fbpx
Connect with us
  • Elysium

Premium content

Drug candidate shows promising results for treating neurodegenerative diseases

Published

on

French biopharmaceutical company Axoltis Pharma has announced promising results from its phase 1b clinical trial evaluating NX210c - an innovative therapy for neurodegenerative diseases and traumas.

Read this and more exclusive content every day as an NR Times online subscriber. Just £2.99 a month, cancel anytime.


Login Join Now

HIWIN

Trending